Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden

被引：5

作者：

Valachis, Antonis ^{[1
]}

Sundqvist, Marie ^{[2
]}

Carlsson, Lena ^{[3
]}

Li, Bing ^{[4
]}

Chiesa, Flaminia ^{[4
]}

Uhde, Milica ^{[4
]}

Sanglier, Thibaut ^{[5
]}

机构：

[1] Orebro Univ, Fac Med & Hlth, Dept Oncol, SE-70182 Orebro, Sweden

[2] Kalmar Cty Hosp, Dept Surg, Breast Unit, Kalmar, Sweden

[3] Sundsvall Cty Hosp, Dept Oncol, Sundsvall, Sweden

[4] IQVIA, RWAS, Stockholm, Sweden

[5] F Hoffmann La Roche Ltd, PHC Data Sci, Basel, Switzerland

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 23期

关键词：

breast cancer; HER2-positive; real-world setting; subcutaneous; trastuzumab; METASTATIC BREAST-CANCER; BIOSIMILAR TRASTUZUMAB; BUDGET IMPACT;

D O I：

10.2217/fon-2019-0160

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: We aimed to describe the use of subcutaneous (sc.) trastuzumab use in a real-world setting. Patients & methods: This retrospective cohort study evaluated electronic medical records of patients with early breast cancer and trastuzumab use from January 2010 to February 2018 in three hospitals in Sweden. Results: In total, 363 patients received trastuzumab during study period. Of these, 217 (59.8%) patients started treatment with sc. trastuzumab and 146 (40.2%) with intravenous trastuzumab. After sc. trastuzumab approval, use of sc. trastuzumab increased from 70.2% in 2014 to 100% in 2017. Since 2013, 34 of 35 (97.4%) patients who started with intravenous trastuzumab switched to sc. formulation. Conclusion: Trastuzumab sc. quickly became the prevailing formulation for treatment in HER2-positive early breast cancer.

引用

页码：2733 / 2741

页数：9

共 15 条

[1] Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia [J].

Cesarec, August ;

Likic, Robert .

APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) :277-286

[2] Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review [J].

Dawood, Shaheenah ;

Broglio, Kristine ;

Buzdar, Aman U. ;

Hortobagyi, Gabriel N. ;

Giordano, Sharon H. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :92-98

[3] A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer [J].

De Cock, Erwin ;

Pivot, Xavier ;

Hauser, Nik ;

Verma, Sunil ;

Kritikou, Persefoni ;

Millar, Douglas ;

Knoop, Ann .

CANCER MEDICINE, 2016, 5 (03) :389-397

[4] Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update [J].

Denduluri, Neelima ;

Chavez-MacGregor, Mariana ;

Telli, Melinda L. ;

Eisen, Andrea ;

Graff, Stephanie L. ;

Hassett, Michael J. ;

Holloway, Jamie N. ;

Hurria, Arti ;

King, Tari A. ;

Lyman, Gary H. ;

Partridge, Ann H. ;

Somerfield, Mark R. ;

Trudeau, Maureen E. ;

Wolff, Antonio C. ;

Giordano, Sharon H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) :2433-+

[5] Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients [J].

Farolfi, Alberto ;

Silimbani, Paolo ;

Gallegati, Davide ;

Petracci, Elisabetta ;

Schirone, Alessio ;

Altini, Mattia ;

Masini, Carla .

ONCOTARGET, 2017, 8 (46) :81343-81349

[6] Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update [J].

Giordano, Sharon H. ;

Temin, Sarah ;

Chandarlapaty, Sarat ;

Crews, Jennie R. ;

Esteva, Francisco J. ;

Kirshner, Jeffrey J. ;

Krop, Ian E. ;

Levinson, Jennifer ;

Lin, Nancy U. ;

Modi, Shanu ;

Patt, Debra A. ;

Perlmutter, Jane ;

Ramakrishna, Naren ;

Winer, Eric P. ;

Davidson, Nancy E. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) :2736-+

[7] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission [J].

Haq, R. ;

Gulasingam, P. .

CURRENT ONCOLOGY, 2016, 23 (02) :91-95

[8] One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis [J].

Inno, Alessandro ;

Barni, Sandro ;

Ghidini, Antonio ;

Zaniboni, Alberto ;

Petrelli, Fausto .

BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) :247-254

[9]

Jackisch C, 2017, P 2017 SAN ANT BREAS

[10] Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial [J].

Joensuu, Heikki ;

Fraser, Judith ;

Wildiers, Hans ;

Huovinen, Riikka ;

Auvinen, Paivi ;

Utriainen, Meri ;

Nyandoto, Paul ;

Villman, Kenneth K. ;

Halonen, Paivi ;

Granstam-Bjorneklett, Helena ;

Lundgren, Lotta ;

Sailas, Liisa ;

Turpeenniemi-Hujanen, Taina ;

Tanner, Minna ;

Yachnin, Jeffrey ;

Ritchie, Diana ;

Johansson, Oskar ;

Huttunen, Teppo ;

Neven, Patrick ;

Canney, Peter ;

Harvey, Vernon J. ;

Kellokumpu-Lehtinen, Pirkko-Liisa ;

Lindman, Henrik .

JAMA ONCOLOGY, 2018, 4 (09) :1199-1206

← 1 2 →